Lung Cancer Trials Ask AI to find trials
TerminatedEarly Phase 1NCT01707823
Official study title

Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer

Study summary

This pilot clinical trial studies low-dose acetylsalicylic acid in treating patients with stage I-III non-small cell lung cancer. Studying samples of urine and blood from patients with cancer in the laboratory may help doctors learn more about changes in biomarkers that occur during treatment with acetylsalicylic acid

Ask AI to explain this study
Start here

Key things to know

Main goalBasic Science

This describes the study’s primary purpose.

What is being studiedacetylsalicylic acid and laboratory biomarker analysis

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable · Recurrent or relapsed

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 14, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Early Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Vanderbilt-Ingram Cancer Center

Study sponsor

01
Study overview

What this study is about

Purpose
Basic Science
Study type
Interventional
Phase
Early Phase 1
Sponsor
Vanderbilt-Ingram Cancer Center
Interventions being studied
Drug: acetylsalicylic acid; Other: laboratory biomarker analysis
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Early-stage or resectable→Recurrent or relapsed→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Have confirmed (stage IIIb-IV) or recurrent non-small cell lung cancer, adenocarcinoma histology
  • Understand and voluntarily sign an informed consent document prior to any study related assessments or procedures are conducted
  • Anticipated that they will complete all study procedures
  • Ability to swallow pills
  • No aspirin in the last 7 days
Reasons someone may not be able to joinExclusion criteria
  • Know allergy to aspirin or other nonsteroidal anti-inflammatory drugs
  • History of allergic reaction to aspirin or other non-steroidal anti-inflammatory drugs, including ibuprofen
  • Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Vanderbilt-Ingram Cancer CenterNashville, Tennessee

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 14, 2020. Always confirm current availability with the study team.

View original record ↗